相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Richard Cathomas et al.
EUROPEAN UROLOGY (2022)
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles et al.
ANNALS OF ONCOLOGY (2022)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Sijia Ren et al.
FRONTIERS IN IMMUNOLOGY (2021)
Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma
Ana M. Novakovic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.
Joel W. Neal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer et al.
NATURE MEDICINE (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Yuxiao Song et al.
FRONTIERS IN IMMUNOLOGY (2020)
Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Joya-Rita Hindy et al.
FUTURE ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma
Magdalena Zajac et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
Yongfeng Wu et al.
FRONTIERS IN ONCOLOGY (2019)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
Incorporating VEGF-targeted therapy in advanced urothelial cancer
Sujata Narayanan et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer
Igor M. Bondarenko et al.
BMC CANCER (2015)
Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model
Stephanie Du Four et al.
ONCOIMMUNOLOGY (2015)
Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation
Huaqin Yuan et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
Chandra P. Belani et al.
BMC CANCER (2014)
Population pharmacokinetic analysis of axitinib in healthy volunteers
May Garrett et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
M. F. Kozloff et al.
BRITISH JOURNAL OF CANCER (2012)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
HS Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
